CCNE1 and breast carcinoma: In conclusion, the results of the present study suggest that evaluation of cyclin E expression levels might help to select the most appropriate treatment for cancer patients, mainly breast cancer patients, by reserving anthracycline treatment to patients whose tumours do not overexpress this molecule.